4Jantumen IT,Muhoneu TT,Kataja W,et al.5-HT3 recep- tor antagonists in the prophylaxis of acute vomiting in- duced by moderately emetongenic chemotherapy- a ran- domized study[J].Eur J Cnaeer, 1993,29 (12) : 1669. 被引量：1
5Minami M,Endo T,Hirafuji M,et al.Pharmaeologieal as- pects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity[J].Pharmacol Ther, 2013,99 (2) : 149-165. 被引量：1
6Eisenberg P, Figueroa-Vadillo J, Zamora R, et al.Improved prevention of moderately emetogenic chemotherapy-in- duced nausea and vomiting with palonosetron,a pharma- cologically novel 5-HT3 receptor antagonist :results of a phase Ⅲ ,single-dose trial versus dolasetren[J].Cancer, 2003,98 ( 11 ) : 2473-2482. 被引量：1
7Janelsins MC, Tejani MA, Kamen C, et al. Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients[J]. Expert Opin Pharmacot her, 2013,14 (6) : 757- 766. 被引量：1
8Bhandari PR. Recent advances in pharmacotherapy of chemother- apy-induced nausea and vomiting[J]. J Adv Pharm Technol Res, 2012,3(4) : 202-209. 被引量：1
9Herrstedt J, Roila F. Chemotherapy-induced nausea and vomiting : ES- MO clinical recommendations for prophylaxis[J]. Ann Oncol, 2009,20 (Suppl 4) :156-158. 被引量：1
10Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice[J]. Nat Clin Pract Oncol, 2008,5 (1) 32-43. 被引量：1
